Cardinal Health Expands Solutions to Mitigate Missed Cancer Screenings


Posted: October 25, 2021 at 11:20 a.m. EDT|Update: 15 minutes ago

DUBLIN, Ohio, 25 October 2021 / PRNewswire / – Cardinal Health (NYSE: CAH) today announced that its cancer screening offerings from FUJIFILM Healthcare Americas Corporation and Polymedco, which can be performed either outside a doctor’s office or with procedures less invasive, can help fight the increase in cancer-related deaths. due to advanced diagnoses1 delays related to the pandemic.

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, day surgery centers, clinical laboratories and physician offices in the whole world. (PRNewsfoto / Cardinal Health)

“The pandemic has changed the landscape of traditional diagnostic methods and is pushing the health sector to assess screenings differently,” added Chris Kerski, Managing Director and Senior Vice President of Cardinal Health Laboratory Products. “We are adding new testing solutions to our portfolio to reduce barriers to screening and support patient-directed cancer screens. “

Colon Cancer

According to a report published in JAMA Oncology2, nearly 10 million breast, colon and prostate cancer screenings have been missed in the United States since the start of the pandemic. Researchers recently reported a drop of more than 40% in colon cancer diagnoses alone during the pandemic, a statistic that points to missed screenings, no fewer cases3.

“Missed screening increases the likelihood of a diagnosis of advanced cancer, which is associated with a poor prognosis,” says Nicolas sullivan, Ph.D., senior product manager at Cardinal Health Laboratory Products with a background in cancer biology and clinical laboratory medicine. “This high number of missed tests during the pandemic has the potential to impact the outcomes of cancer patients for years to come.”

During the pandemic, some health systems and health plans began to proactively send screening collection kits to patients, rather than waiting for patients to show up for a routine visit or colonoscopy.4. Cardinal Health works with Polymedco to offer OC-Auto®FIT, which detects small amounts of blood in the stool – an early indication of colon cancer5. Unlike a colonoscopy, patients do not have to prepare for the test and can collect stool samples at home.

Liver cancer

Liver cancer is one of the three leading causes of cancer-related deaths worldwide6 more than 700,000 deaths per year7.

In november 2020, Cardinal Health became the first distributor of Fujifilm’s innovative solution, the µTASWako® i30 immunoassay system testing AFP-L3 and DCP hepatic biomarkers using a simple blood sample. These biomarkers help assess the risk of patients with chronic liver disease of developing hepatocellular carcinoma (HCC), the most common type of liver cancer.8.

Monitoring for HCC is essential for people at risk for liver cancer because of its lethality. A recent study9 reported that liver cancer surveillance declined dramatically during the pandemic, and that “a delay of just a few months in HCC surveillance can be catastrophic for patients, as the tumor volume doubling time of HCC is of 85.7 days “. Only 20% of patients at risk of developing liver cancer are monitoredten.

Cardinal Health now offers Fujifilm’s automated solution to improve liver cancer surveillance programs for clinical laboratory customers.

Access to cancer screening

As a trusted advisor in the clinical laboratory market, Cardinal Health champions the important role diagnostic tests play in improving healthcare.

“These critical extensions to our cancer screening offerings, coupled with our robust anatomical pathology and laboratory kit services, underscore our commitment to making healthcare more accessible for patients. We must remain vigilant in preventive care through the use of easily accessible screening tools. and increase awareness of the secondary impacts of the pandemic, ”Kerski explains.

To learn more about Cardinal Health lab products and cancer screening, visit

About Cardinal Health
Cardinal Health is a pharmaceutical distributor, a global manufacturer and marketer of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years of business, operations in more than 35 countries and approximately 44,000 employees worldwide, Cardinal Health is essential to care. Information about Cardinal Health is available at

Media: Cari Wildasinn, [email protected] and (614) 757-8287
Investors: Kevin Moran, [email protected] and (614) 757-7942

1 Man, Alice. ASCO Post. March 10, 2021. COVID-19 fallout: decrease in cancer screening and increase in cancer-related deaths.

2 Ronald C. Chen, MD, MPH1; Kevin Haynes, PharmD, MSCE2; Simo Du, MBBS, MHS2; et al John Barron, PharmD2; Aaron J. Katz, PharmD, PhD3. JAMA Oncology. April 29, 2021; 1; 7 (6): 878-884. doi: 10.1001 / jamaoncol.2021.0884. Association of the cancer screening deficit in the United States with the COVID-19 pandemic.

3 Murez, Cara. WebMD. October 4, 2021. Colon cancer diagnoses have dropped 40% in a pandemic, and that’s not good news.

4 Mary Chris Jaklevic, MSJ. JAMA Network. December 23, 2020. The pandemic highlights home colon cancer screening tests.

5 American Cancer Society. June 29, 2020. Signs and Symptoms of Colorectal Cancer.

6 World Health Organization. September 21, 2021. Cancer fact sheet.

7 American Cancer Society. January 12, 2021. Key statistics on liver cancer.

8 Mayo Clinic. May 18, 2021. Liver cancer.

9 Hidenori Toyoda, Daniel Q. Huang, Michael H. Le, Mindie H. Nguyen. Communications in hepatology. July 17, 2020. Liver care and monitoring: The global impact of the COVID-19 pandemic.

ten Neehar D Parikh, Anand S Mehta, Amit G Singal, Timothy Block, Jorge A. Marrero, Anna SF Lok. National Library of Medicine. June 1, 2021. Biomarkers for the early detection of hepatocellular carcinoma.

View original content to download multimedia:

SOURCE Cardinal Health

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.


About Author

Comments are closed.